Effectiveness of resveratrol against cardiovascular disease

Mini-Reviews in Organic Chemistry

Volumn 7, Issue 4, 2010, Pages 256-261

  Rahman, M Mamunur ^a   Bak, Istvan ^b   Das, Dipak K ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Cardioprotection; Heart; Ischemia reperfusion; Redox regulation; Resveratrol

Indexed keywords

BIOCHEMISTRY; CARDIOLOGY; DISEASES;

ANTI-AGING; CARDIOPROTECTION; CARDIOVASCULAR DISEASE; HEALTH BENEFITS; HEALTH CONDITION; ISCHAEMIA-REPERFUSION; ISCHEMIC HEART DISEASE; NUTRITIONAL SUPPLEMENTS; REDOX-REGULATION; SIDE EFFECT;

RESVERATROL;

EID: 77958189242     PISSN: 1570193X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157019310792246418     Document Type: Article

References (76)

1. Farina, A.; Ferranti, C.; Marra, C. An improved synthesis of resveratrol. Nat.Prod. Res., 2006, 20(3), 247-52.
2. Stojanovic, S.; Sprinz, H.; Brede, O. Efficiency and mechanism of theantioxidant action of trans-resveratrol and its analogues in the radicalliposome oxidation. Arch. Biochem. Biophys., 2001, 391(1), 79-89.
3. Constant, J. Alcohol, ischemic heart disease, and the French paradox. Coron.Artery Dis., 1997, 8(10), 645-649.
4. Cottart, C.H.; Nivet-Antoine, V.; Laguillier-Morizot, C.; Beaudeux, J.L. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res.,2010, 54(1), 7-16.
5. Renaud, S.C.; Gueguen, R.; Schenker, J.; d'Houtaud, A. Alcohol and mortal-ity in middle-aged men from eastern France. Epidemiology, 1998, 9(2),184-188.
6. Kundu, J.K.; Surh, Y.J. Cancer chemopreventive and therapeutic potential ofresveratrol: mechanistic perspectives. Cancer Lett., 2008, 269(2), 243-261.
7. Bishayee, A. Cancer prevention and treatment with resveratrol: from rodentstudies to clinical trials. Cancer Prev. Res., 2009, 2(5), 409-418.
8. Marambaud, P.; Zhao, H.; Davies, P. Resveratrol promotes clearance ofAlzheimer's disease amyloid-beta peptides. J. Biol. Chem., 2005, 280(45),37377-37382.
9. Tangkeangsirisin, W.; Serrero, G. Resveratrol in the Chemoprevention and Chemotherapy of Breast Cancer. Bagchi, D.; Preuss, H.G. Eds. Phytopharmaceuticals in Cancer Chemoprevention. Boca Raton: CRC Press.2005, 449-463.
10. Chen, Z.H.; Hurh, Y.J.; Na, H.K. Resveratrol inhibits TCDD-inducedexpression of CYP1A1 and CYP1B1 and catechol estrogen-mediatedoxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis, 2004, 25(10), 2005-2013.
11. Joe, A.K.; Liu, H.; Suzui, M.; Vural, M.E.; Xiao, D.; Weinstein, I.B. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changesin biomarker expression in several human cancer cell lines. Clin. CancerRes., 2002, 8(3), 893-903.
12. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P.J.; Poosala, S.; Becker, K.G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K.W.; Spencer, R.G.; Lakatta, E.G.; Le Couteur, D.; Shaw, R.J.; Navas, P.; Puigserver, P.; Ingram, D.K.; de Cabo, R.; Sinclair, D.A. Resveratrol improves health and survival of mice on a highcalorie diet. Nature, 2006,444(7117), 337-342.
13. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.L.; Scherer, B.; Sinclairm D.A. Small molecule activators of sirtuins extend Saccharo-myces cerevisiae lifespan. Nature, 2003, 425(6954), 191-196.
14. Bass, T.M.; Weinkove, D.; Houthoofd, K.; Gems, D.; Partridge, L. Effects ofresveratrol on lifespan in Drosophila melanogaster and Caenorhabditiselegans. Mech. Ageing Dev., 2007, 128(10), 546-52.
15. Khot, U.N.; Khot, M.B.; Bajzer, C.T.; Sapp, S.K., Ohman, E.M.; Brener, S.J.; Ellis, S.G.; Lincoff, A.M.; Topol, E.J. Prevalence of conventional riskfactors in patients with coronary heart disease. JAMA, 2003, 290(7),898-904.
16. Buja, L.M.; Eigenbrodt, M.L.; Eigenbrodt, E.H. Apoptosis and necrosis. Basic types and mechanisms of cell death. Arch. Pathol. Lab Med., 1993,117(12), 1208-14.
17. Kirk, R.I.; Deitch, J.A.; Wu, J.M.; Lerea, K.M. Resveratrol decreases earlysignaling events in washed platelets but has little effect on platelet in wholeblood. Blood Cells Mol. Dis., 2000, 26(2), 144-150.
18. Wallerath, T.; Deckert, G.; Ternes, T.; Anderson, H.; Li, H.; Witte, K.; Förstermann, U. Resveratrol, a polyphenolic phytoalexin present in red wine,enhances expression and activity of endothelial nitric oxide synthase.Circulation, 2002, 106(13), 1652-1658.
19. Szewczuk, L.M.; Forti, L.; Stivala, L.A.; Penning, T.M. Resveratrol is aperoxidase-mediated inactivator of COX-1 but not COX-2: a mechanisticapproach to the design of COX-1 selective agents. J. Biol. Chem., 2004,279(21), 22727-22737.
20. Gurusamy, N.; Lekli, I.; Mukherjee, S.; Ray, D.; Ahsan, K.M.; Gher-ghiceanu, M.; Popescu, M.L.; Das, K.D. Cardioprotection by resveratrol: anovel mechanism via autophagy involving the mTORC2 pathway. Cardio-vasc. Res., 2010, 86(1), 103-112.
21. Rosa, M.L.; Ana, I.; Romero-Perez, Andrew, L.; Waterhouse, M.; Carmen dela Torre-Boronat. Direct HPLC Analysis of cis- and trans-Resveratrol andPiceid Isomers in Spanish Red Vitis vinifera Wines. J. Agric. Food Chem.,1995, 43(2), 281-283.
22. Prokop, J.; Abrman, P.; Seligson, A.L.; Sovak, M. Resveratrol and its glyconpiceid are stable polyphenols. J. Med. Food, 2006, 9(1), 11-14.
23. Bertelli, A.A.; Gozzini, A.; Stradi, R.; Stella, S.; Bertelli, A. Stability ofresveratrol over time and in the various stages of grape transformation. Drugs Exp. Clin. Res., 1998, 24(4), 207-211.
24. Camont, L.; Cottart, C.; Rhayem, Y.; Nivet-Antoine, V.; Djelidi, R.; Collin, F.; Beaudeux, J.L.; Bonnefont-Rousselot, D. Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions. Anal. Chim.Acta, 2009, 634(1), 121-128.
25. Burns, J.; Yokota, T.; Ashihara, H.; Lean, M.E.J.; Crozier, A. Plant foodsand herbal sources of resveratrol. J. Agric. Food Chem., 2002, 50(11),3337-3340.
26. Jane, H. Resveratrol. Oregon State University. The Linus Pauling InstituteMicronutrient Information Center, USA 2005.
27. Zachary, M.S. Quest for youth drives craze for 'wine' pills. Wall Street J. (30 November 2006). Retrieved 2008-02-02.
28. Ribeiro de Lima, M.T.; Waffo-Teguo, P.; Teissedre, P.L.; Pujolas, A.; Vercauteren, J.; Cabanis, J.C.; Mérillon, J.M. Determination of stilbenes(trans-astringin, cis- and transpiceid, and cis- and trans-resveratrol) in Portuguese wines. J. Agric. Food Chem., 1999, 47(7), 2666-2670.
29. Burkon, A.; Somoza, V. Quantification of free and proteinboundtrans-resveratrol metabolites and identification oftrans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol me-tabolites in human plasma. Mol. Nutr. Food Res., 2008, 52(5), 549-557.
30. Boocock, D.J.; Patel, K.R.; Faust, G.E.; Normolle, D.P.; Marczylo, T.H.; Crowell, J.A.; Brenner, D.E.; Booth, T.D.; Gescher, A.; Steward, W.P. Quantitation of trans-resveratrol and detection of its metabolites in humanplasma and urine by high performance liquid chromatography. J. Chroma-togr. B. Anal. Technol. Biomed. Life Sci., 2007, 848, 182-187.
31. Urpi-Sarda, M.; Zamora-Ros, R.; Lamuela-Raventos, R.; Cherubini, A.; Jauregui, O., de la Torre, R.; Covas, M.I.; Estruch, R.; Jaeger, W.; Andres-Lacueva, C. HPLC-tandem mass spectrometric method to characterizeresveratrol metabolism in humans. Clin. Chem., 2007, 53(2), 292-299.
32. Walle, T.; Hsieh, F.; DeLegge, M.H.; Oatis, J.E.; Walle, U.K. Highabsorption but very low bioavailability of oral resveratrol in humans. DrugMetab. Dispos., 2004, 32(12), 1377-1382.
33. Abd El-Mohsen, M.; Bayele, H.; Kuhnle, G.; Gibson, G., Debnam, E., KailaSrai, S., Rice-Evans, C., Spencer, J.P. Distribution of [3H] trans-resveratrolin rat tissues following oral administration. Br. J. Nutr., 2006, 96(1), 62-70.
34. Yu, C.; Shin, Y.G.; Chow, A.; Li, Y.; Kosmeder, J.W.; Lee, Y.S.; Hirschel-man, W.H.; Pezzuto, J.M.; Mehta, R.G.; van Breemen, R.B. Human, rat, andmouse metabolism of resveratrol. Pharm. Res., 2002, 19(12), 1907-1914.
35. Wang, L.X.; Heredia, A.; Song, H.; Zhang, Z.; Yu, B.; Davis, C.; Redfield, R. Resveratrol glucuronides as the metabolites of resveratrol in humans:characterization, synthesis, and anti-HIV activity. J. Pharm. Sci., 2004,93(10), 2448-2457.
36. Boocock, DJ.; Faust, G.E.; Patel, K.R.; Schinas, A.M.; Brown, V.A.; Ducharme, M.P.; Booth, T.D.; Crowell, J.A.; Perloff, M.; Gescher, A.J.; Steward, W.P.; Brenner, DE. Phase I dose escalation pharmacokinetic studyin healthy volunteers of resveratrol, a potential cancer chemopreventiveagent. Cancer Epidemiol. Biomarkers Prev., 2007, 16(6), 1246-1252.
37. Wenzel, E.; Somoza, V. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res., 2005, 49(5), 472-481.
38. Vitaglione, P.; Sforza, S.; Galaverna, G.; Ghidini, C.; Caporaso, N.; Vescovi, P.P.; Fogliano, V.; Marchelli, R. Bioavailability of trans-resveratrol from redwine in humans. Mol. Nutr. Food Res., 2005, 49(5), 495-504.
39. Gescher, A.J.; Steward, W.P. Relationship between mechanisms,bioavailibility, and preclinical chemopreventive efficacy of resveratrol: aconundrum. Cancer Epidemiol. Biomarkers Prev., 2003, 12(10), 953-957.
40. Das, D.K.; Maulik, N. Protection against free radical injury in the heart andcardiac performance. In: Sen Cen, K.; Packer, L.; Hanninen, O. Eds. Exer-cise and Oxygen Toxicity. Amsterdam: Elsevier Science, 1995, pp. 359-388.
41. Cave, A.C.; Breweer, A.C.; Narayanapanicker, A.; Ray, R.; Grieve, D.J.; Walker, S.; Shah, A.M. NADPH oxidases in cardiovascular health and disease. Anitoxid. Redox Singnal., 2006, 8(5-6), 691-728.
42. Stocker, R., Keaney, JF Jr. Role of oxidative modifications in atherosclerosis. Physiol. Rev., 2004, 84(4), 1381-1478.
43. Sato, M.; Ray, P.S.; Maulik, N.; Engelman, R.M.; Bertelli, A.A.E.; Bertelli, A.; Das D.K. Myocardial protection with red wine extract. J. Cardiovasc.Pharmacol., 2000, 35(2), 263-268.
44. Bulmer, A.C., Blanchfield, J.T., Toth, I., Fassett, R.G., Coombes, J.S. Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis, 2008, 199(2), 390-396.
45. Hung, L.M.; Su, M.J.; Chen, J.K. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic. Biol. Med., 2004, 36(6), 774-781.
46. Wallerath, T.; Deckert, G.; Ternes, T.; Anderson, H.; Li, H.; Witte, K.; Forstermann, U. Resveratrol, a polyphenolic phytoalexin present in red wine,enhances expression and activity of endothelial nitric oxide synthase. Circulation, 2002, 106(13), 1652-1658.
47. Das, S.; Alagappan, V.K.T.; Bagchi, D.; Sharma, H.S.; Maulik, N.; Das, D.K. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrolconsumption A potential mechanism for resveratrol preconditioning of theheart. Vascul. Pharmacol., 2005, 42(5-6), 281-289.
48. Hsieh, T.C.; Juan, G.; Darzynkiewicz, Z.; Wu, J.M. Resveratrol increasesnitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation byperturbing progression through S and G2. Cancer Res., 1999, 59(11),2596-2601.
49. Imamura, G.; Bertelli, A.A.; Bertelli, A.; Otani, H.; Maulik, N.; Das, D.K.Pharmacological preconditioning with resveratrol: an insight with iNO-Sknockout mice. Am. J. Physiol., 2002, 282(6), 1996-2003.
50. Das, S.; Falchi, M.; Bertelli, A.; Maulik, N.; Das, D.K. Attenuation of ischemia/reperfusion injury in rats by the anti-inflammatory action of resveratrol. Arzneimittelforschung, 2006, 56(10), 700-706.
51. Delal, C.A., Astra, C.A., Villegas, I. Resveratrol as an anti-inflammatory andanti-aging agent: mechanisms and clinical implications. Mol. Nutr. FoodRes., 2005, 49(5), 405-430
52. Pendurthi, U.R., Williams, J.T., Rao, L.V. Resveratrol, a polyphenolic com-pound found in wine, inhibits tissue factor expression in vascular cells: Apossible mechanism for the cardiovascular benefits associated with moderateconsumption of wine. Arterioscler. Thromb. Vasc. Biol., 1999, 19(2),419-426.
53. Bisht, K., Wagner, K.H., Bulmer, A.C. Curcumin, resveratrol and flavonoidsas anti-inflammatory, cyto-and DNA-protective dietary compounds. Toxicology, 2009, (in press) doi:10.1016/j.tox.2009.11.008
54. Pacher, P, Mabley, J.G., Soriano, F.G., Liaudet, L., Komjati, K., Szabó, C. Endothelial dysfunction in aging animals,the role of poly (ADP-ribose) po-lymerase activation. Br. J. Pharmacol., 2002, 135(6),1347-1350.
55. Csiszar, A., Pacher, P., Kaley G., Ungvari, Z. Role of oxidative and nitrosative stress, longevity genes and poly(ADP-ribose) polymerase in cardiovascular dysfunction associated with aging. Curr. Vasc. Pharmacol., 2005, 3(3),285-291.
56. Malik, G.; Gorbounov, N.; Das, S.; Gurusamy, N.; Otani, H.; Maulik, N.; Goswami, S.; Das, D.K. Ischemic preconditioning triggers nuclear transloca-tion of thioredoxin and its interaction with Ref-1 potentiating a survival sig-nal through the PI-3-kinase-Akt pathway. Antioxid. Redox Signal., 2006,8(11-12), 2101-2109.
57. Dudley, J.; Das, S.; Mukherjee, S.; Das, D.K. Resveratrol, a uniquephytoalexin present in red wine, delivers either survival signal or death signalto the ischemic myocardium depending on dose. J. Nutr. Biochem., 2009,20(6), 443-452.
58. Alcaín, F.J.; Villalba, J.M. Sirtuin activators. Expert Opin. Ther. Pat., 2009,19(4), 403-414.
59. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; Geny, B.; Laakso, M.; Puigserver, P.; Auwerx, J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1. Cell, 2006, 127(6), 1109-1122.
60. Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E.A.; Caldwell, S.D.; Napper, A.; Curtis, R.; DiStefano, P.S.; Fields, S.; Bedalov, A.; Kennedy, B.K. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem., 2005, 280(17), 17038-17045.
61. Pacholec, M.; Chrunyk, B.A.; Cunningham, D.; Flynn, D.; Griffith, D.A.; Griffor, M.; Loulakis, P.; Pabst, B.; Qiu, X.; Stockman, B.; Thanabal, V.; Varghese, A.; Ward, J.; Withka, J.; Ahn, K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem., 2010,285(11), 8340-8351.
62. Stefani, M.; Markus, M.A.; Lin, R.C.; Pinese, M.; Dawes, I.W.; Morris, B.J. The effect of resveratrol on a cell model of human aging. Ann. N.Y. Acad.Sci., 2007, 1114, 407-418.
63. Brunet, A.; Sweeney, L.B.; Sturgill, J.F.; Chua, K.F.; Greer, P.L.; Lin, Y.; Tran, H.; Ross, S.E.; Mostoslavsky, R.; Cohen, H.Y.; Hu, L.S.; Cheng, H.L.; Jedrychowski, M.P.; Gygi, S.P.; Sinclair, D.A.; Alt, F.W.; Greenberg, M.E. Stress-dependent regulation of FOXO transcription factors by the SIRT1deacetylase. Science, 2004, 303(5666), 2011-2015.
64. Kops, G.J.; Dansen, T.B.; Polderman, P.E.; Saarloos, I.; Wirtz, K.W.; Cof-fer, P.J.; Huang, T.T.; Bos, J.L.; Medema, R.H.; Burgering, B.M. Forkheadtranscription factor FOXO3a protects quiescent cells from oxidative stress. Nature, 2002, 419(6904), 316-321.
65. Macmillan-Crow, L.A.; Cruthirds, D.L. Invited review: manganese superoxide dismutase in disease. Free Radic. Res., 2001, 34(4), 325-336.
66. Das, D.K. Thioredoxin regulation of ischemic preconditioning. Antioxid.Redox Signal., 2004, 6(2), 405-412.
67. Turoczi, T.; Chang, V.W.; Engelman, R.M.; Maulik, N.; Ho, Y.S.; Das, D.K. Thioredoxin redox signaling in the ischemic heart: an insight with transgenicmice overexpressing Trx1. J. Mol. Cell Cardiol., 2003, 35(6), 695-704.
68. Edwards, M.; Rassin, D.k.; Izumi, T.; Mitra, S.; Perez-Polo, J.R. APE/Ref-1responses to oxidative stress in aged rats. J. Neurosci. Res., 1998, 54(5),635-638.
69. Gustafsson, A.B.; Gottlieb, R.A. Recycle or die: the role of autophagy incardioprotection. J. Mol. Cell Cardiol., 2008, 44(4), 654-661.
70. Brito, P.M.; Devillard, R.; Negre-Salvayre, A.; Almeida, L.M.; Dinis, T.C.; Salvayre, R.; Augé, N. Resveratrol inhibits the mTOR mitogenic signalingevoked by oxidized LDL in smooth muscle cells. Atherosclerosis, 2009,205(1), 126-134.
71. Vaz-da-Silva, M.; Loureiro, A.I.; Falcao, A.; Nunes, T.; Rocha, J.F.; Fer-nandes-Lopes, C.; Soares, E.; Wright, L.; Almeida, L.; Soares-da-Silva, P.Effect of food on the pharmacokinetic profile of transresveratrol. Int. J. Clin.Pharmacol. Ther., 2008, 46(11), 564-570.
72. Almeida, L.; Vaz-da-Silva, M.; Falcao, A.; Soares, E.; Costa, R.; Loureiro, A.I.; Fernandes-Lopes, C.; Rocha, J.F.; Nunes, T.; Wright, L.; Soares-da-Silva, P. Pharmacokinetic and safety profile of trans-resveratrol ina rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res.,2009, 53(Suppl 1), S7-S15.
73. Crowell, J.A.; Korytko, P.J.; Morrissey, R.L.; Booth, T.D.; Levine, B.S. Resveratrol-associated renal toxicity. Toxicol. Sci., 2004, 82(2), 614-619.
74. Juan, M.E.; Vinardell, M.P.; Planas, J.M. The daily oral administration ofhigh doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr.,2002, 132(2), 257-260.
75. Williams, L.D.; Burdock, G.A.; Edwards, J.A.; Beck, M.; Bausch, J. Safetystudies conducted on high-purity transresveratrol in experimental animals. Food Chem. Toxicol., 2009, 47(9), 2170-2182.
76. Mukherjee, S.; Dudley, J.I.; Das, D.K. Dose-dependency of resveratrol inproviding health benefits. Dose-response, 2010 (in press) doi:10.2203/dose-response.09-015. Mukherjee.